Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare Biotechnology

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger)

Bullboard Posts

Comment by funky99on Mar 04, 2016 11:56am

105 Views

Post# 24622510

RE:RE:RE:RE:RE:RE:Antibe Therapeutics Reports Q3 2016 Interim Financial

They 1st started to get revenu on Q4 2015 for 2.1 mil with the acquisition. They will need to skim a little the expense of Citaginex to pull an EPS. With Knight Therapeutics involved and invested here I am not worried. They also secured right and distribution of Antibe drug pipeline. ATB-346 is going into phase II.

Agree that some brokers tried to trigger stop loss or accumulate and squeeze the weak heads but most shares are held tightly. There is a high insider ownership.

I think this is way undervalued don't understand what keeps the share price at these level other than brokers game. Patience is required in the market.

Bullboard Posts

Canadian government to fund Electric Royalties portfolio property